Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Stoke Therapeutics Inc(STOK)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for STOK
10/23/2026: STOK (1-star) is currently NOT-A-BUY. Pass it for now.
Stoke Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines to treat genetic diseases by upregulating protein expression. Its primary strength lies in its proprietary TANGO platform, which offers a unique approach to addressing conditions caused by haploinsufficiency. The company's main investment story centers on the potential of its lead candidate, STK-001, to effectively treat Dravet syndrome. However, Stoke faces significant execution and binary risks common to clinical-stage firms, including the dependency on successful trial results and the need for ongoing capital. This stock is best suited for risk-tolerant investors who should closely monitor clinical data updates and the company's cash runway.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to clinical breakthroughs, but it carries significant risk due to its pre-commercial stage. |
| Momentum investor | Mixed fit | Momentum may be driven by clinical trial catalysts, but the stock is subject to high volatility contingent on data readouts. |
| Value investor | Weak fit | Stoke lacks earnings or dividends, making it unsuitable for traditional value-based investment strategies. |
| Dividend investor | Weak fit | The company does not pay dividends and is focused exclusively on capital-intensive R&D. |
| Low-risk investor | Weak fit | The inherent uncertainty of clinical development makes this an inappropriate choice for low-risk, capital-preservation portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks frequently experience sharp price movements based on trial results and regulatory updates. |
| Valuation risk | High | Valuation is speculative, as it is based on the future probability of success rather than existing cash flows. |
| Competition risk (RNA therapeutics) | Medium / high | The sector is crowded with well-funded competitors developing alternative gene-modulating technologies. |
| Business quality | Medium | While the technology is innovative, the company is still unproven in bringing a drug to market. |
| Dividend income | Low / none | Investors should expect zero income generation from this stock. |
| Execution risk | High | The company faces significant hurdles in clinical trial design, patient recruitment, and regulatory approval. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -0.72% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.62B USD | Price to earnings Ratio - | 1Y Target Price 46.46 |
Price to earnings Ratio - | 1Y Target Price 46.46 | ||
Volume (30-day avg) 1.1M shares | Beta 1.26 | 52 Weeks Range 20.32 - 40.22 | Updated Date 10/25/2026 |
52 Weeks Range 20.32 - 40.22 | Updated Date 10/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.38 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Research & Development | Focus on TANGO-based platform and pipeline drug candidates like STK-001. | The company does not yet sell products; it creates value by progressing experimental drugs toward potential regulatory approval. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 204.08 | Enterprise Value 1.11B | Price to Sales(TTM) 58.57 |
Enterprise Value 1.11B | Price to Sales(TTM) 58.57 | ||
Enterprise Value to Revenue 5.58 | Enterprise Value to EBITDA 26.37 | Shares Outstanding 64.53M | Shares Floating 45.61M |
Shares Outstanding 64.53M | Shares Floating 45.61M | ||
Percent Insiders 3.68 | Percent Institutions 125.42 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.